Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 3/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | PRCP | P42785 | 1/20 | 0.46 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.46 |
| ▸ | LIPE | Q05469 | 3/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16002995 | 0.88 | RBP4 (0.55) | RBP4SIGMAR1POLBCNR1SYK | |
| SCHEMBL13826657 | 0.81 | MAPK1 (0.56) | SIGMAR1C3AR1KDM4EEPHX2ALDH1A1 | |
| SCHEMBL16689582 | 0.79 | RBP4 (0.73) | RBP4PRCP | |
| SCHEMBL13826434 | 0.79 | SYK (0.46) | SYKC3AR1KDM4EALDH1A1 | |
| SCHEMBL24011242 | 0.78 | SIGMAR1 (0.46) | RBP4SIGMAR1POLBLIPEKDM4E | |
| SCHEMBL16000512 | 0.77 | MEN1 (0.70) | SIGMAR1POLBCNR1SYKEPHX2 | |
| SCHEMBL8671332 | 0.76 | RBP4 (0.60) | RBP4SIGMAR1POLBCNR1PRCP | |
| SCHEMBL27491505 | 0.76 | RBP4 (0.60) | RBP4SIGMAR1POLBCNR1PRCP | |
| SCHEMBL4377755 | 0.76 | HRH3 (0.62) | RBP4CNR1KDM4EALDH1A1 | |
| SCHEMBL24011148 | 0.75 | RAB9A (0.54) | SIGMAR1POLBEPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145391-B2 | Bipyridylaminopyridines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-09-04 | — | — | US | disclosed |
| WO-2012154518-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | SYK, BTK, LCK | RBP4 4832/4885SIGMAR1 2509/4885POLB 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.